[
  {
    "ts": "2025-11-04T21:05:00+00:00",
    "headline": "Gilead Sciences to Present at Upcoming Investor Conferences",
    "summary": "FOSTER CITY, Calif., November 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
    "url": "https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-210500937.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "bf9992c6-a847-3502-aa66-212d265536c9",
      "content": {
        "id": "bf9992c6-a847-3502-aa66-212d265536c9",
        "contentType": "STORY",
        "title": "Gilead Sciences to Present at Upcoming Investor Conferences",
        "description": "",
        "summary": "FOSTER CITY, Calif., November 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
        "pubDate": "2025-11-04T21:05:00Z",
        "displayTime": "2025-11-04T21:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/e40881497dbe783cf6a64dc2d50c529c",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r4j7BTj6A18RI6b6LdUq0Q--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e40881497dbe783cf6a64dc2d50c529c.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3NhagbX6w05MgK_aUWNWtg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e40881497dbe783cf6a64dc2d50c529c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-210500937.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T13:38:00+00:00",
    "headline": "HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline",
    "summary": "Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.",
    "url": "https://finance.yahoo.com/news/hiv-livdelzi-fuel-gilds-q3-133800300.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "06f95ff8-5a17-3cba-af96-ae8ba198b9b1",
      "content": {
        "id": "06f95ff8-5a17-3cba-af96-ae8ba198b9b1",
        "contentType": "STORY",
        "title": "HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline",
        "description": "",
        "summary": "Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.",
        "pubDate": "2025-11-04T13:38:00Z",
        "displayTime": "2025-11-04T13:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V0K9NHfyQItlfJrmH40Oow--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZZlN12HiCVB5ZUMKhsVieA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hiv-livdelzi-fuel-gilds-q3-133800300.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hiv-livdelzi-fuel-gilds-q3-133800300.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]